Navigation Links
Genesis Biopharma Mentioned Favorably in BioMedReports Article
Date:5/22/2012

LOS ANGELES, May 22, 2012 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer immunotherapies, was mentioned favorably in an article in BioMedReports that was issued earlier today. The article can be accessed at the following link:

http://www.biomedreports.com/2012052295011/darling-dendreon-continues-taking-huge-hits.html

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is engaged in the development and commercialization of autologous cell therapies for the treatment of various cancers. The company's lead product candidate, Contego, is a ready-to-infuse autologous cell therapy that utilizes tumor infiltrating lymphocytes for the treatment of patients with Stage IV metastatic melanoma. Contego is based on a currently available physician-sponsored investigational therapy at the National Cancer Institute, MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute for the treatment of Stage IV metastatic melanoma. 

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the proposed public offering and the intended use of proceeds from the offering. The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including market conditions, risks associated with the cash requirements of the company's business and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission, and represent the company's views only as of the date they are made and should not be relied upon as representing the company's views as of any subsequent date. The company does not assume any obligation to update any forward-looking statements.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Genesis Biopharma Issues Letter To Shareholders
2. Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants
3. ValGenesis Suite 2.5 Certified by SAP as Powered by SAP NetWeaver®
4. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
5. ThermoGenesis Announces Approval of AXP® by India Ministry of Health
6. ThermoGenesis Announces Acceptance of AXP® Submission by Regulatory Body in China
7. Genesis Biosciences Announces New Hire and Promotions on Operational and Scientific Staff
8. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2011 on September 12, 2011
9. Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
10. Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors
11. Genesis Biopharma Names David Voyticky to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... San Francisco, CA (PRWEB) , ... June 23, ... ... capture (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase ... DIA Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
Breaking Biology Technology:
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
Breaking Biology News(10 mins):